Da Zen Theranostics

About:

Da Zen Theranostics develop a product that can target cancer cells, function as a contrast agent to improve the visibility of cancer cells.

Website: http://www.dazenthera.com

Description:

Da Zen Theranostics develop a product that can target cancer cells, function as a contrast agent to improve the visibility of cancer cells. It functions as a contrast agent to improve the visibility of cancer cells during diagnostic imaging and deliver a therapeutic drug to destroy cancerous cells. The product will be based on a chemical compound that was created by Dr. Maged Henary, associate professor of chemistry at Georgia State. Henary’s chemical compound, a heptamethine cyanine also known to the scientific community as MHI-148, is already being used internationally in cancer imaging research. The company was founded in 2017 and is based in San Jose, California.

Total Funding Amount:

$2.3M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

San Jose, California, United States

Founded Date:

2017-01-01

Founders:

Leland W.K. Chung

Number of Employees:

1-10

Last Funding Date:

2019-07-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai